Drug Shortage Report for SANDOZ-CARBAMAZEPINE CR
| Report ID | 225212 |
| Drug Identification Number | 02261847 |
| Brand name | SANDOZ-CARBAMAZEPINE CR |
| Common or Proper name | CARBAMAZEPINE CR |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | CARBAMAZEPINE |
| Strength(s) | 400MG |
| Dosage form(s) | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL ORAL |
| Packaging size | 100MRT |
| ATC code | N03AF |
| ATC description | ANTIEPILEPTICS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2024-04-15 |
| Estimated end date | 2024-08-30 |
| Actual end date | 2024-07-02 |
| Shortage status | Resolved |
| Updated date | 2025-03-12 |
| Company comments | Product available under allocation. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 4600 RUE ARMAND-FRAPPIER SAINT-HUBERT, QUEBEC CANADA J3Z 1G5 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.